Key result
Circulating biomarkers such as cell-free DNA, mitochondrial DNA, and specific microRNA panels may help discriminate heart failure phenotypes and improve personalized therapy in dilated cardiomyopathy.
Why the study?
A deeper knowledge of molecular networks leading to acute injury and apoptosis is needed to reveal novel circulating biomarkers to better discriminate HF phenotypes, identify patients at risk of heart transplant or graft reject, and improve personalised therapy.
Design
Review
Authors
Loading...
Does not support routine clinical use; leaves open prospective validation of these biomarkers in dilated cardiomyopathy.
Epigenetic liquid biomarkers such as cfDNA and miRNAs hold promise for improving phenotypic discrimination and personalized management in advanced heart failure.
Mansueto et al. (2020) conducted a review in Dilated cardiomyopathy and heart failure. Epigenetic-sensitive liquid biomarkers (cfDNA, mtDNA, miRNAs) was evaluated. Circulating biomarkers such as cell-free DNA, mitochondrial DNA, and specific microRNA panels may help discriminate heart failure phenotypes and improve personalized therapy in dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: